PAQR6 and cholangiocarcinoma: When we repeated our analysis for overall expression profiling of 35 CCA tumors, across all immune subtypes, we only obtained significant differential expression patterns for PAQR6, which may be attributable to a small sample size of available clinical data for CCAs, in TCGA, regarding immune subtype classifications (Figure 3(C-2)).